Blog

  • SMX and CETI Unite to Give Europe Fashion’s Most Powerful Weapon: Trust (NASDAQ:SMX)

    NEW YORK, NY / ACCESS Newswire / September 29, 2025 / Europe has long been the beating heart of global fashion, but now it intends to become the brain as well. While designers in Paris and Milan set the trends on the runway, the continent’s regulators have been setting just as aggressive targets behind the scenes. The EU’s Digital Product Passport rules, ESG mandates, and Green Deal initiatives all point to one thing: traceability is no longer optional. It’s the law. And the brands that want to thrive under this regime need more than ambition. They need proof.

    That’s where the partnership between SMX (NASDAQ:SMX) and CETI, the European Center for Innovative Textiles, takes center stage. Based in Lille, CETI is a hub of R&D firepower, and SMX is bringing the molecular-level tech that finally turns recycling and authentication into measurable realities. By embedding invisible fingerprints into fibers and tying them to blockchain passports, they’re not talking about traceability in theory. They’re operationalizing it at an industrial scale. This isn’t about testing samples in a lab. It’s about creating market-ready fabrics that carry their credentials from the moment they leave the loom.

    The implications are massive. Lille is now positioned as Europe’s launch pad for textile circularity, an epicenter where compliance meets competitiveness. The brands that plug into this system won’t just be checking regulatory boxes; they will also be leveraging the system to drive growth. They’ll be setting the global standard, exporting textiles with built-in trust that can cross borders, enter finance systems, and hold value in resale markets. Counterfeiters, once experts at slipping through loopholes, will find themselves locked out entirely. Europe’s message is clear: if it doesn’t carry proof, it doesn’t carry value.

    Europe’s Competitive Edge

    The Green Deal and Digital Product Passport requirements are no longer distant talking points. They’re active levers reshaping how textiles are produced, sold, and financed. For companies that comply, the rewards are enormous. Verified recycled content can fetch higher margins, sustainability reports suddenly become bulletproof, and ESG-linked financing starts flowing with lower risk premiums. CETI’s pilot lines turn compliance into a competitive edge, and SMX’s molecular markers make sure no counterfeit can piggyback off the system. In a sector where billions are lost to fake fabrics and fraudulent claims, that’s not just progress. It’s a paradigm shift.

    Luxury fashion will benefit, but so will sportswear, industrial fabrics, and technical textiles. By embedding trust directly into the material, the entire ecosystem gains a multiplier effect. Supply chains move faster, regulators have enforceable data, and consumers gain confidence that the clothes on their backs are what they claim to be. Proof becomes Europe’s new export, not just the fabrics themselves. That’s how you win markets.

    Platforms like eBay show why this matters globally. They already have rules in place to fight fakes, but rules aren’t enough without the tools to enforce them at speed and scale. Scanners tied to molecular markers would make their efforts airtight, instantly authenticating a watch, a handbag, or a jacket before it ever hits the buyer’s doorstep. Europe’s proof-first model is the playbook, and platforms everywhere will be forced to follow.

    The New Standard

    The counterfeit industry has thrived on gaps, exploiting weak enforcement and opaque supply chains. But Europe just closed the gap. Lille’s CETI, armed with SMX technology, isn’t running pilots for show. It’s demonstrating to the world that circularity can be verifiable, profitable, and enforceable. The EU’s leadership on this front isn’t just bureaucratic muscle. It’s the foundation of a new global textile economy, one where every fiber carries a passport and every recycled material commands its true price.

    Fashion has always been about staying ahead, but this is different. This is about Europe using regulation and technology as weapons to protect its competitiveness and ensure standards are met, while simultaneously burying counterfeiters in the rubble of their old business model.

    From luxury brands to industrial suppliers, the rules of the game just changed. And the scoreboard isn’t counting logos anymore. It’s counting the proof that SMX and CETI can provide.

    About SMX

    As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

    Forward-Looking Statements

    The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

    EMAIL: info@securitymattersltd.com

    SOURCE: SMX (Security Matters)

    View the original press release on ACCESS Newswire

  • Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

    The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of the skin using dissolvable Doxorubicin-containing Microneedle arrays (D-MNA) representing ~$2 billion in potential market opportunity

    The Company plans to complete patient recruitment for SKNJCT-003 before the end of Q4 2025 and to request End-of-Phase 2 (EOP2) with the FDA in Q1 2026

    PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September 29, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce positive feedback from Type C meeting with United States Food and Drug Administration (FDA).

    The purpose of the Type C meeting was to discuss the design, endpoints, and other key protocol elements for the clinical development of doxorubicin containing microneedle array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin.

    The FDA provided clarity and further alignment that a relative bioavailability study with the Company’s D-MNA product to treat BCC administered under certain conditions could provide support towards establishing a clinical bridge for the 505(b)(2) regulatory pathway as well as help satisfy the bioavailability requirement of the Company’s D-MNA product as stated in 21CFR320.21. More specifically, the FDA provided positive and constructive feedback on a number of topics for the continued development of Skinject including, but not limited to: the appropriate primary endpoint for the next study; proposed patient population definition, including tumor size limits, location restrictions, and histological confirmation requirements; proposed randomized, double-blind, placebo-controlled, study design for future studies that are intended to demonstrate the effectiveness of D-MNA in treating BCC; and current safety assessments for the proposed study.

    In anticipation of future pivotal studies, the FDA also provided recommendations to continue to optimize formulation and microneedle design, integrate an adhesive layer to affix the microneedle system to the body, and incorporate the use of an applicator to consistently apply the product to the application site.

    “Establishing 505(b)(2) as a regulatory pathway to bring to market our novel, non-invasive Skinject D-MNA treatment to cure BCC of the skin, is a game changer” stated Dr. Raza Bokhari, Medicus’s Executive Chairman & CEO, “by leveraging existing doxorubicin safety data, we will not only realize substantial drug development cost savings but also time savings compared to a traditional full development program. As we plan to complete patient recruitment for SKNJCT-003 before the end this year and request an EOP2 meeting with the FDA in Q1 2026, our confidence is increasing that Skinject may become commercially viable sometime in 2027”.

    The Company is currently conducting a Phase 2 clinical study for SKNJCT-003 in nine (9) clinical sites across the United States which commenced randomizing patients in August 2024. In March 2025, the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more than 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board approved to increase the number of participants in SKNJCT-003 to ninety (90) subjects. The Company is expanding its trial sites in Europe and has randomized more than 75% of the ninety (90) participants expected to be randomized in the study.

    The Company also has a clinical study (SKNJCT-004) currently underway in the United Arab Emirates (UAE). The study is expected to randomize thirty-six (36) patients in six (6) sites in the UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.

    In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

    Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

    For further information contact:

    Carolyn Bonner, President and Acting Chief Financial Officer
    (610) 636-0184
    cbonner@medicuspharma.com

    Anna Baran-Djokovic, SVP Investor Relations
    (305) 615-9162
    adjokovic@medicspharma.com

    About Medicus Pharma Ltd.

    Medicus Pharma Ltd. (Nasdaq:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.

    SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

    In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston Based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

    In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

    Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

    In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

    In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

    In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

    In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients.

    Cautionary Notice on Forward-Looking Statements

    Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the commencement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. . Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

    SOURCE: Medicus Pharma Ltd

    View the original press release on ACCESS Newswire

  • LHH Executive Search Research Finds Nearly 60% of Leaders Plan to Change Roles Within the Next Three Years

    Two-thirds of executives plan to leave their current company, signaling a need to rethink succession planning and build stronger leadership pipelines.

    NEW YORK CITY, NY / ACCESS Newswire / September 29, 2025 / LHH, the integrated professional talent solutions provider and global business unit of the Adecco Group, today releases its report reviewing the current state of executive search and transition processes.

    View from the C-Suite: Executive Talent Strategies for a New Era, draws on perspectives from more than 4,600 executives worldwide and highlights the trends reshaping leadership, from evolving career paths to the skills organizations value most in a rapidly changing business environment. The report also outlines strategies for building leadership teams capable of navigating complexity, driving transformation, and creating lasting impact.

    Nearly six in ten executives expect to make a career move within the next three years, indicating a need for organizations to future-proof leadership strategies with succession planning and talent strategies that retain and develop top leaders. The report offers actionable insights to help organizations elevate executive search as a strategic priority, build world-class leadership teams, and equip leaders to succeed in an era of rapid change and unprecedented opportunity.

    One in three newly appointed executives says they do not feel confident in their ability to perform within the first year of a new role, and almost just as many executives lack confidence in their leadership team’s ability to perform. Of the executives surveyed, 30% also indicated wanting to develop new skills as a top-rated reason for their departure. Trust, support and the ongoing skills-gaps across all stages of talent development, including leadership, point to broader overarching challenges of continued vacancies if there is risk of underprepared successors.

    At the same time, the skill set organizations look for in leaders is shifting. Technical expertise is no longer the sole differentiator, but rather soft skills such as collaboration, strategic thinking and communication top the list of must-have qualities. Executives who can adapt, inspire and drive transformation are in highest demand, underscoring the value of human-centered leadership.

    However, technology is still crucial to understanding the leaders at the forefront of workforce transformation. More than a third of executives say AI and digital fluency are the most critical capabilities for leadership teams. Leading AI success across organizations requires senior leaders who can integrate the technology responsibly, aligned with strategy and scale across the enterprise.

    “Leadership is being redefined. To stay ahead, organizations need executive talent strategies that identify and recruit leaders with the right skills and provide the right support, empathy and partnership they need to succeed in complex, changing environments,” says Nicole Gable, North America Recruitment Solutions president at LHH. “The executives who make the biggest impact are those who blend human-centered skills with the ability to leverage technology to communicate vision, drive results and lead with purpose.”

    As the trusted leader in executive search, LHH connects organizations to leaders who bring expertise, passion and fresh perspectives. With a distinctly human approach and a focus on long-term partnerships, LHH delivers a boutique experience that creates long-lasting, strategic leadership outcomes from Executive Search to Executive Interim Management and leadership workforce planning from Talent Mapping to Executive Assessments.

    To read the full report and learn more about LHH Executive Search, visit: https://info.lhh.com/gbl/en/executive-search

    ###

    About LHH

    LHH empowers professionals and organizations to achieve bold ambitions and secure lasting impact through unique advisory services and professional talent solutions.

    LHH’s full suite of offerings connects solutions that are traditionally siloed, making LHH a single talent partner for organizations. In a rapidly evolving landscape with complex challenges, we create value across the entire professional talent journey. From hiring great people, developing skills and nurturing leaders, to advancing individuals to the next stage of their careers, LHH makes talent a competitive edge.

    We believe the future of work lies at the intersection of exceptional human care and innovation. Powered by science, technology and proprietary data analytics, LHH’s approach is crafted to align with business strategies and cultures, delivering powerful, sustainable and measurable impact.

    LHH has a team of over 12,000 professionals, across 60+ countries and more than 50 years of experience. As part of the Adecco Group, we bring together global excellence, local knowledge and centralized coordination for thousands of companies and millions of people worldwide.

    Recruitment. Development. Career Transition.

    LHH. A beautiful working world.

    To learn more about LHH, visit: lhh.com.

    Media Contact

    PR@lhh.com

    SOURCE: LHH

    View the original press release on ACCESS Newswire

  • Physicians for Informed Consent Distributes Landmark Vaccine Book to Trump, Vance and Congress, Shows Childhood Vaccines Not Proven Safer Than Diseases They Target

    Physicians for Informed Consent Distributes Landmark Vaccine Book to Trump, Vance and Congress, Shows Childhood Vaccines Not Proven Safer Than Diseases They Target

    The nonprofit organization calls on federal leaders to withhold funds from states restricting vaccine exemptions

    NEWPORT BEACH, CA / ACCESS Newswire / September 29, 2025 / As part of its national Education Initiative on Vaccine Safety, Physicians for Informed Consent (PIC) has delivered its landmark book, “Vaccines and the Diseases They Target: An Analysis of Vaccine Safety and Epidemiology” (the Silver Booklet), to every member of Congress, as well as President Donald Trump and Vice President JD Vance. The book equips lawmakers with scientific and statistical data showing that, for normal-risk U.S. children,vaccines have not been proven safer than the diseases they intend to prevent.

    PIC Education Initiative on Vaccine Safety
    PIC Education Initiative on Vaccine Safety
    Silver Booklet sent to Trump, Vance and all members of Congress

    The education campaign, which aims to elevate children’s health, underscores PIC’s mission to safeguard informed consent in vaccination and end mandatory vaccination laws. In a letter that accompanied the book, PIC states:

    “From an ethical standpoint, any medical mandate must, at the very least, be shown to deliver more benefit than harm. As you work to improve children’s health in the face of rising chronic illness, we respectfully urge you to review the evidence we present, which indicates that current vaccine mandates are not scientifically substantiated and may, in fact, pose greater risks than the diseases they target. In the meantime, we ask that federal funding be withheld from states that do not safeguard religious or philosophical exemptions to vaccine mandates for school attendance.”

    In August, PIC sent an urgent letter to HHS Secretary Robert F. Kennedy Jr., requesting an immediate review of childhood vaccine policies and a reconsideration based on risk-benefit analysis.

    “We believe federal leaders will be empowered by the information in this book, which includes side-by-side comparisons of disease risks vs. vaccine risks, with over 400 references and color illustrations,” said Shira Miller, M.D., PIC founder and president. “By providing the Silver Booklet directly to lawmakers, we’re ensuring they have access to the data that challenges long-standing assumptions about vaccine safety and mandatory childhood vaccination.”

    What’s in the Silver Booklet:

    • Clear descriptions of infectious childhood diseases, symptoms, treatment options, and the risk of serious outcomes

    • Insights into vaccine effectiveness, side effects, and safety profiles

    • Data-driven comparisons of the risks posed by diseases versus their related vaccines

    • Figures and illustrations to make complex data more reader-friendly

    “Many lawmakers are unaware that vaccine safety research leaves critical questions unanswered,” said Greg Glaser, Esq., PIC general counsel and national coalition director. “The Silver Booklet advances evidence-based dialogue and equips the President, Vice President and Congress to enact policies that protect children’s health.”

    Physicians for Informed Consent urges every public official and health authority to read the new book and confront the disconnect between mandatory vaccination and scientific evidence.

    To learn more about the book or to support the PIC Education Initiative on Vaccine Safety, visit silverbooklet.org.

    Contact Information

    Greg Glaser
    General Counsel
    info@picphysicians.org
    925-642-6651

    .

    SOURCE: Physicians for Informed Consent

    View the original press release on ACCESS Newswire

  • SK tes Receives Approval of Targets for Reducing Greenhouse Gas Emissions

    SK tes Receives Approval of Targets for Reducing Greenhouse Gas Emissions

    Validation from Science Based Targets initiative demonstrates that the global leader in ITAD services is committed to mitigating climate change through sustainable business practices.

    SINGAPORE, SG / ACCESS Newswire / September 29, 2025 / SK tes, a global leader in sustainable IT asset disposition (ITAD) and technology lifecycle services, announces that the Science Based Targets initiative has validated the company’s greenhouse gas (GHG) emissions inventory and reductions targets.

    The action confirms that SK tes has developed plans that will allow the company to meet both its short-term emissions goals as well as its net-zero carbon by 2050 goal, and demonstrates that SK tes is committed to environmentally sustainable business practices.

    “SBTi’s validation of our emissions targets shows that SK tes is committed to significantly reduce our carbon footprint, both from our internal processes and in how we do business with clients and partners worldwide,” said Alvin Piadasa, group sustainability director at SK tes.”As the first ITAD to make this commitment, we aim to inspire others to act — our impact goes beyond reuse; it drives real environmental change.”

    With 40-plus facilities worldwide, SK tes assists clients in more than 100 countries in managing the commissioning, deployment, and retirement of technology devices and components. It provides comprehensive lifecycle services for technology devices, from deployment to decommissioning to disposition.

    The Science Based Targets initiative and SBTi Services develop standards, tools and guidance based on the latest findings in climate science that allow organizations to reduce their greenhouse gas emissions to levels needed to prevent catastrophic global heating. Businesses that receive SBTi Services validation demonstrate to their customers and investors that they are taking responsibility for preventing the worst impacts of climate change.

    The SK tes GHG emissions reduction targets, as validated by SBTI Services, include:

    Near-term targets: Reduce absolute Scope 1 and 2 GHG emissions 42% by 2030 from a 2023 base year, and reduce scope 3 GHG emissions 51.6% per dollar of value add within the same timeframe.

    Long-term targets: Reduce absolute Scope 1, 2 and 3 GHG emissions 90% by 2050 from a 2023 base year.

    Overall Net-Zero Target: Commitment to reach net-zero greenhouse gas emissions across the value chain by 2050.

    Scope 1 emissions are greenhouse gases that an organization emits from sources it owns or controls directly, such as exhaust from an engine or furnace. Scope 2 emissions are indirect, such as the organization’s purchase of electricity, steam, heat, or cooling produced by a utility or other generator.

    Scope 3 emissions, also known as lifecycle or value chain emissions, include those generated across a product’s lifecycle — for example, fuel burned to manufacture or operate it, or emissions from employees commuting to work.

    In baseline year 2023, SK tes emitted about 6,400 tons of Scope 1 and 2 GHG emissions and was responsible for another 54,600 tons of Scope 3 emissions. Under its targets, the company would reduce Scope 1 and 2 emissions to about 3,700 tons by 2030 and about 6000 tons by 2050. Scope 3 emissions intensity would fall to 28,000 tons by 2030 and absolute emissions by about 150,000 tons by 2050 taking into account compounded business growth.

    In its validation report, SBTi concluded that SK tes’ “targeted near-term reduction between the base year and the most recent year leads to emissions reductions in line with a 1.5°C pathway,” the limit set in the international treaty on climate change known as the Paris Agreement, adopted by 195 nations in 2015.

    “SK tes believes that the company and the planet are inextricably connected, and by creating a pathway that aligns with the targets of the Paris Agreement, we are taking action to ensure a bright and prosperous future for both,” Piadasa said.

    To learn more about SK tes services and its commitment to sustainability, visit https://www.sktes.com/.

    About SK tes

    Since our formation in 2005, SK tes, a subsidiary of SK ecoplant, has grown to become a global leader in sustainable battery recycling and technology lifecycle services. We provide comprehensive services for battery recycling, extracting scarce materials from used batteries at purity rates high enough that they can be reused in the manufacturing supply chain.

    SK tes has over 40 owned facilities across 22 countries offering unmatched service-level consistency, consistent commercials, lower logistics costs, local compliance experts in-region, support in local time zones and languages, and a deep understanding of transboundary movement globally.

    Contact Information

    Kristine Kearney
    kristine.kearney@sktes.com
    +44 7706 352 702

    Buse Kayar
    busek@accessnewswire.com

    .

    SOURCE: SK tes

    Related Images

    SK tes X Science Based Targets
    SK tes X Science Based Targets
    SK tes X Science Based Targets
    SK tes X Science Based Targets
    SK tes X Science Based Targets
    SK tes X Science Based Targets

    View the original press release on ACCESS Newswire

  • Index’25 – the World’s First AI-Search Conference

    Index’25 – the World’s First AI-Search Conference

    Pepper unites Global leaders in Marketing, AI, and Technology to decode the Future of SEO in the AI Era

    NEW YORK CITY, NY / ACCESS Newswire / September 29, 2025 / Pepper Content today announced Index’25: Decoding AI Search, the world’s first conference dedicated to Generative Engine Optimization (GEO). The event, scheduled for October 1, 2025, marks a watershed moment in how marketers will navigate the rapidly shifting landscape of AI-driven discovery.

    Speakers at Index'25
    Speakers at Index’25
    Top Speakers at Index’25

    Registration for Index’25 is now open. For more information and to secure your spot, visit https://www.peppercontent.io/index-25/

    For decades, the rules of search and visibility were set by platforms. Artificial intelligence has not simply introduced incremental changes to marketing-it has created a tectonic shift. Index’25 will bring together CMOs, marketing leaders, SEO practitioners, founders, investors, and technology innovators to explore what this new world of AI-native discovery means for the future of growth.

    “Once in a generation, technology doesn’t just improve – it changes the very way we see the world. That’s what’s happening to search right now.” said Anirudh Singla, Co-founder & CEO of Pepper Content.

    A Global Line-Up of Visionaries

    Index’25 will host 25+ marquee speakers who are at the forefront of marketing, and AI innovation. Among the headline names are:

    • Neil Patel – Global Marketing Influencer

    • Paul Daugherty – Former CTO & CIO, Accenture

    • Sydney Sloan – Former CMO, G2

    • Eric Solomon – Former CMO, Spotify

    • Angelique Bellmer Krembs – Former CMO, PepsiCo

    • Mandy Dhaliwal – CMO, Nutanix

    • Anand Swaminathan – Senior Partner, McKinsey & Company

    • Joyce Hwang – Head of Marketing, Dropbox

    • Guy Yalif – Chief Evangelist, Webflow

    • Vamshi Sri – CMO, SASE, Palo Alto Networks

    • Linda Caplinger – Head of SEO and AI Search, NVIDIA

    These leaders will share insights across a range of sessions, fireside chats, and workshops, creating a blueprint for how enterprises and practitioners can navigate GEO and AI-powered search.

    Event Highlights

    • Keynotes on the future of AI search and generative discovery

    • Panels and Firesides featuring CMOs, founders, and VCs

    • Workshops tailored for both enterprise leaders and SEO practitioners

    • Product Launch of Pepper’s latest GEO innovation

    Beyond the Conference

    Index’25 is not just a one-day event. It will spark a sustained movement in how companies operationalize GEO and AI search. Post-conference, Pepper will host:

    • GEO Implementation Webinars showcasing real case studies

    • Private Roundtables & Dinners across major U.S. cities including New York, Chicago, San Francisco, Seattle, Los Angeles, and Austin

    • 1:1 GEO Audits and Clinics designed to help enterprises build long-term competitive moats

    Why Index’25 Matters

    The rise of AI-native search challenges the traditional playbooks of digital visibility. Keywords and rankings are no longer the only currency. Instead, the future of discovery lies in trust, memory, and retrieval at machine scale. Index’25 will provide the community, frameworks, and tools to help businesses lead-not lag-in this transformation.

    About Pepper Content

    Pepper is the Content-Led Growth Engine that combines AI agents with human expertise to accelerate content velocity, increaseamplify brand visibility across LLMs, search, and social, and drive predictable organic growth for forward-thinking enterprise brands.

    Contact Information

    Kishan Panpalia
    Founding Team
    kishan@peppercontent.io
    4157545133

    .

    SOURCE: Pepper Content Inc.

    View the original press release on ACCESS Newswire

  • Kidoodle.TV Honored With Media Impact Award for Outstanding Brand Safety Strategy

    Kidoodle.TV Honored With Media Impact Award for Outstanding Brand Safety Strategy

    Recognition underscores decade-long commitment to safe, kid-friendly streaming, and family-first technology.

    CALGARY, AB / ACCESS Newswire / September 29, 2025 / Kidoodle.TV®, owned by A Parent Media Co. Inc. (APMC), the leading Safe Streaming™ service for children, has been awarded the prestigious Outstanding Brand Safety Strategy award at Cynopsis Media’s annual Media Impact Awards. The service was also named as a finalist for Best Connected TV (CTV) Platform, highlighting its innovative technology and seamless user experience. These awards celebrate the trailblazers and innovators redefining the future of media and content distribution. 

    This recognition marks a significant milestone in Kidoodle.TV’s mission to create a trusted and secure streaming environment for kids and families. For over a decade, the service has delivered accessible, safe, and age-appropriate content to millions of households around the world. 

    The win highlights Kidoodle.TV’s human-first approach to content and ad screening, which is key to its proprietary ad technology, Safe Exchange. Unlike traditional, algorithm-driven systems, this innovative solution combines human verification with detailed metadata tagging to filter programmatic ads in real time. This ensures every piece of content remains brand-safe and kid-friendly, providing peace of mind for both families and advertisers.

    “At a time when algorithms dominated, we chose a different path, one that puts human-judgement and child safety first,” said Neil Gruninger, President & CEO at APMC. “This award affirms our original mission: to raise the standard for online safety and give audiences and brands a place they can truly trust. It’s a win for our team and, most importantly, for the millions of families who have welcomed Kidoodle.TV into their homes.”

    The company’s commitment to safety goes beyond content, extending into the broader experience of digital parenting.

    “Parents often feel guilt around screen time, but we believe it can be a positive force when it’s done right,” said Jeremy Mason, Chief Brand Officer at APMC. “By investing in meaningful features like the Kidoodle® Parents Room and Teachers’ Corner, we’re giving families safe and enriching choices to make screen time count.”

    This recognition is the latest in a series of achievements for the company, following its recent Webby Award win for Best Streaming Service. In the last three years, APMC has expanded its offering to include Glitch+, the official Dude Perfect streaming service, Victory+, and its ever-important Feeding Families program, all reinforcing its commitment to safety, trust and audience-first innovation.

    Kidoodle.TV will be honored at the Cynopsis Media Impact Awards on October 14th in New York City. 

    For more information on Kidoodle.TV, visit www.kidoodle.tv.

    ABOUT APMC and Kidoodle.TV

    A Parent Media Co. Inc. (APMC) is a media and technology company focused on providing innovative solutions to consumers and brands. APMC is a leader in Safe Streaming™ delivering an end-to-end solution to brands and platforms with an emphasis on unlocking incremental revenue. Utilizing proprietary streaming and monetization technologies, APMC reaches millions of homes globally through its products including Kidoodle.TV®, Dude Perfect Streaming Service, Glitch+™, Victory+™ and Safe Exchange™. Kidoodle.TV is a Safe Streaming™ service committed to providing children with a safe alternative to stream their favorite TV shows and movies. Available in over 160 countries and territories on thousands of connected devices, Kidoodle® provides peace of mind, with every show* vetted by caring people who are committed to Safe and Free Streaming for Kids™. Kidoodle.TV is available on iOS, Android, Apple TV, Fire TV, LG, Samsung, VIDAA-enabled Hisense TVs, Chromecast, Roku, Vizio SmartCast Amazon, Jio, Xfinity X1, Connected TVs, HTML5 Web, and many other streaming media devices. Kidoodle.TV is certified by the kidSAFE® Seal Program and is the proud recipient of a Webby Award for Best Streaming Service, the Mom’s Choice Award®, a Stevie® Award, platinum winner of the Best Mobile App Award, and Parents’ Picks Award – Best Elementary Products. Visit www.kidoodle.tv to learn more.

    LinkedIn: linkedin.com/company/aparentmediacoinc

    X: https://x.com/aparentmediaco

    Contact Information

    Madeleine Moench
    madeleine@newswire.com

    Jeremy Mason
    Chief Brand Officer
    media@aparentmedia.com

    .

    SOURCE: A Parent Media Co. Inc.

    Related Images

    View the original press release on ACCESS Newswire

  • Brenmiller Signs System Purchase Agreement with Baran Energy for bGen ZERO Systems at Tempo Beverages and Wolfson Medical Center

    Brenmiller Signs System Purchase Agreement with Baran Energy for bGen ZERO Systems at Tempo Beverages and Wolfson Medical Center

    Brenmiller to receive milestone-based payments for the sale of the bGen systems, profit sharing from future income generated on the projects, and maintenance and operations service revenue

    Transaction provides non-dilutive capital injection as part of capital-efficient growth strategy, powering Brenmiller to advance its broader global project pipeline of commercial opportunities valued at over $500 million

    Milestone marks a significant evolution in the relationship between Brenmiller and Baran following the signing of a strategic collaboration agreement in February 2025

    ROSH HA‘AYIN AND BEIT DAGAN, ISRAEL / ACCESS Newswire / September 29, 2025 / Brenmiller Energy Ltd. (“Brenmiller”, “Brenmiller Energy”, or the “Company”) (Nasdaq:BNRG), a leading global provider of Thermal Energy Storage (“TES”) solutions for industrial and utility customers, and Baran Energy Ltd., the energy subsidiary of the Baran Group Ltd. (“Baran”), an international engineering company that provides management, design and construction solutions for large-scale infrastructure projects, today announced that the companies have signed a System Purchase Agreement (the “Agreement”) for the completion and operational launch of two bGen ZERO TES systems currently in development in Brenmiller’s portfolio.

    Brenmiller to Receive Milestone-Based Payments and Profit Sharing

    Baran will become the owner of the bGen TES projects at Tempo Beverages Ltd. (“Tempo”) and Wolfson Medical Center, representing a total of 44 MWh, and will pay Brenmiller for the acquisition based on project execution milestones achieved during the construction and commissioning phases. Brenmiller will also receive profit sharing on the projects based on revenues from end customers. Brenmiller retains all intellectual property and will continue to provide, and be paid for, operations and maintenance on the bGen ZERO systems.

    Strong Long-Term Collaboration

    Baran Energy Ltd. is a subsidiary of Baran, Israel’s leading engineering and project execution firm. Baran’s deep expertise in infrastructure development, which includes hundreds of infrastructure projects deployed globally over 40 years, makes them an ideal partner to assist in developing Brenmiller’s current and future TES projects. Baran Energy has a right of first refusal to acquire future bGen projects in Israel, providing Brenmiller the option to leverage Baran’s extensive project execution experience in the industrial sector as well as their financing capabilities.

    Management Commentaries

    “With this agreement and collaboration, we are positioned to significantly accelerate not only the Tempo and Wolfson Medical Center projects, we believe this will also have a positive impact on our entire pipeline of global commercial opportunities and our competitiveness to advance more projects into our portfolio,” said Avi Brenmiller, Chairman and Chief Executive Officer of Brenmiller Energy. “Importantly, while Baran will hold ownership of these two TES projects, Brenmiller remains fully committed and directly involved in the performance and long-term success of these projects which will produce ongoing revenues for our Company.”

    “This collaboration represents the best of both worlds-Brenmiller’s innovation and Baran’s experience in a diversity of energy projects worldwide,” said Hezy Haim, Chief Executive Officer of Baran Energy. “Together, we’re building the foundation for a cleaner, more efficient energy future in Israel and beyond.”

    About bGen™

    bGen™ ZERO is Brenmiller’s TES system, which converts electricity into heat to power sustainable industrial processes at a price that is competitive with natural gas. The bGen™ ZERO charges by capturing low-cost electricity from renewables or the grid and stores it in crushed rocks. It then discharges steam, hot water, or hot air on demand according to customer requirements. The bGen™ ZERO also supports the development of utility-scale renewables by providing critical flexibility and grid-balancing capabilities. bGen™ ZERO was named among TIME’s Best Inventions of 2023 in the Green Energy category and won Gold in the Energy Storage and Management category at the 2025 Edison Awards.

    About Brenmiller Energy Ltd.

    Brenmiller Energy helps energy-intensive industries and power producers end their reliance on fossil fuel boilers. Brenmiller’s patented bGen™ ZERO thermal battery is a modular and scalable energy storage system that turns renewable electricity into zero-emission heat. It charges using low-cost renewable electricity and discharges a continuous supply of heat on demand and according to its customers’ needs. The most experienced thermal battery developer on the market, Brenmiller operates the world’s only gigafactory for thermal battery production and is trusted by leading multinational energy companies. For more information visit the Company’s website at https://bren-energy.com/ and follow the company on X and LinkedIn.

    About Baran Group

    The Baran Group is an international engineering company that provides engineering solutions for the management and design of building, industrial, and technological infrastructures, operating in Israel and abroad. The core activities of the Baran Group include the management, planning, and execution of complex projects in the fields of infrastructure, construction, and integrated industrial systems, energy, agriculture, and water, both in Israel and internationally. The Baran Group offers fully integrated project services, starting from feasibility studies, conceptual preliminary planning, detailed design, procurement services, project management, and supervision of execution, organizing financing packages and full project implementation. The Baran Group employs more than one thousand people, including employees in its foreign subsidiaries. Baran Energy is an energy projects developer focusing on renewable energy, including PV and BESS projects. Baran Energy operates in Israel, the USA, and Europe.

    Forward-Looking Statements:

    This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company uses forward-looking statements when it discusses: the collaboration between the Company and Baran as providing a non-dilutive capital injection as part of a capital-efficient growth strategy , allowing the Company to advance its broader global project pipeline of commercial opportunities valued at over $500 million; future milestone-based payments will be made by Baran to the Company during construction and commissioning; that Baran’s expertise makes them an ideal collaborator and financial partner to assist in developing the Company’s current and future TES projects; the Company’s belief that the Agreement will have a positive impact on its entire pipeline of global opportunities and its competitive ability to advance more projects into its portfolio and that these projects will produce ongoing, recurring revenues for the Company. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect the Company’s results include, but are not limited to: the Company’s planned level of revenues and capital expenditures; risks associated with the adequacy of existing cash resources; the demand for and market acceptance of our products; impact of competitive products and prices; product development, commercialization or technological difficulties; the success or failure of negotiations; trade, legal, social and economic risks; and political, economic and military instability in the Middle East, specifically in Israel. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 4, 2025, which is available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

    Contact: investors@bren-energy.com

    SOURCE: Brenmiller Energy

    View the original press release on ACCESS Newswire

  • Nautical Ventures Expands Electric Division with Exclusive Taiga Personal Watercraft Distribution in Florida

    Nautical Ventures Expands Electric Division with Exclusive Taiga Personal Watercraft Distribution in Florida

    FORT LAUDERDALE, FLORIDA / ACCESS Newswire / September 29, 2025 / Vision Marine Technologies Inc. (NASDAQ:VMAR), a company at the forefront of high-voltage electric propulsion and supported by an award-winning retail network, today announced that its wholly owned subsidiary, Nautical Ventures Group (“Nautical Ventures”), has completed a distribution agreement with Taiga Motors Inc. (“Taiga”) to serve as the exclusive dealer and authorized service provider for Taiga’s electric personal watercraft in major Florida markets.

    This agreement goes beyond a traditional dealership model. Nautical Ventures provides a vertically integrated platform – from marketing and events to retail sales, service, and warranty – all delivered by a salesforce reinforced by Vision Marine’s high-voltage service team expertise already established in Florida. This combination of specialized training, tools, and support reinforces consumer confidence and makes Nautical Ventures the ideal partner in Florida to introduce and sustain next-generation electric products.

    Under the agreement, Nautical Ventures will have exclusive rights to distribute Taiga’s electric personal watercraft across key Florida counties, including Miami-Dade, Broward, Palm Beach, and Hillsborough. Florida remains the epicentre of the U.S. personal watercraft market, reflecting the state’s leadership in recreational boating activity. Globally, the personal watercraft market reached USD 1.9 billion in 2023 and is projected to grow at more than 5% CAGR through 2032, according to Global Market Insights (Global Market Insights – Personal Watercraft Market). This sustained demand reinforces the importance of Florida as the strategic base for Nautical Ventures’ Electric Division.

    “Through Nautical Ventures, we are curating a focused portfolio of electric products that meet clear criteria for our Florida customers – performance, safety, and serviceability,” said Diego N. Conti, Head of Sales at Nautical Ventures. “Taiga’s personal watercraft fits that brief and strengthens the Electric Division’s offering. Our role is to make the right products easy to discover, purchase, and support across our network.”

    Phillip Sudano, Director of Network Operations at Taiga Motors, added: “We’re entering an exciting new chapter at Taiga, with strong momentum behind our recently unveiled MY26 models and expanding partnerships around the globe. Florida is one of the most important watercraft markets in the world, and we’re thrilled to partner with Nautical Ventures and their group of dealerships in Florida. Their forward-thinking approach, deep electric expertise, and proven retail platform make them the perfect partner to introduce and support Taiga’s next-generation watercraft. Together, we’re committed to building a strong foundation with Florida’s boating community as electric adoption accelerates.”

    This expansion reflects the execution of Vision Marine’s dual-pillar growth strategy: advancing proprietary electric propulsion technologies while leveraging Nautical Ventures’ retail and service infrastructure as the adoption engine. With impactful additions such as Taiga’s personal watercraft, alongside SEABOB, Nautical Ventures’ Electric Division is building a curated portfolio of premium electric products. This portfolio complements its ICE boat business, which continues to represent the foundation of current revenues and provides balance to the Company’s scalable model.

    About Vision Marine Technologies Inc. and Nautical Ventures Group
    Vision Marine Technologies Inc. (NASDAQ:VMAR) is at the forefront of high-voltage electric propulsion and electric boating, supported by Nautical Ventures Group, its award-winning retail network in Florida. Vision Marine brings to market the 180 HP E-Motion™ high-voltage electric outboard powertrain, which has been integrated across multiple OEM platforms and is protected by a growing portfolio of patents. Nautical Ventures, operating nine locations with a proven track record in sales and marketing, connects consumers to premium on-water experiences and serves as the adoption engine for Vision Marine’s technology. Together, the two entities unite innovation and execution – advancing proprietary propulsion solutions while providing direct-to-consumer access across both electric and internal combustion product lines.

    About Taiga Motors Inc.
    Taiga Motors Inc. is a Canadian manufacturer of high-performance electric powersports vehicles. Its product portfolio includes electric snowmobiles, personal watercraft, and off-road vehicles, engineered to redefine outdoor recreation with zero emissions and uncompromising performance.

    Forward-Looking Statements
    This press release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Factors that could affect such results include, among others, market adoption, execution of commercial agreements, regulatory developments, and economic conditions. Vision Marine disclaims any obligation to update these statements except as required by law.

    Investor Relations Contact
    Bruce Nurse
    (303) 919-2913
    bn@v-mti.com

    https://investors.visionmarinetechnologies.com

    SOURCE: Vision Marine Technologies Inc

    View the original press release on ACCESS Newswire

  • TruMerit and EnGen Partner to Equip Foreign-Educated Health Professionals With English Skills for Success in Work and Life

    TruMerit and EnGen Partner to Equip Foreign-Educated Health Professionals With English Skills for Success in Work and Life

    PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September 24, 2025 / TruMerit, a leader in global healthcare workforce development, is partnering with EnGen, a workforce-aligned English language learning solution, to support foreign-educated nurses and other healthcare professionals in building the language skills to succeed in English-speaking work environments and to flourish in their new communities.

    This new collaboration enables current and past applicants for TruMerit’s credential evaluation services to purchase individual access to EnGen’s platform and state-of-the-art tools for building English skills. Through targeted, job-specific English training, learners will boost their confidence, enhance their job performance, and prepare for in-demand roles in healthcare systems facing critical staffing shortages.

    EnGen’s innovative approach blends on-demand, AI-powered instruction with human-mediated support, including live online group workshops and coaching. The solution equips working adults with the English skills needed for specific jobs and career paths, including healthcare roles. Stronger English skills not only help them prepare for required language proficiency tests and licensure exams, but also to grow in their careers and thrive in workplace and community life in their new country.

    With thousands of foreign-educated nurses and allied professionals arriving in the U.S. each year to help fill staffing shortages in health systems, strong communication skills are a vital asset, enabling better collaboration, patient care, and overall outcomes. In addition to verification of their education and licensing in their home countries-services that TruMerit already provides-U.S. immigration law requires proof of English language proficiency to ensure clear communication across the healthcare teams and protect patient safety.

    “Under TruMerit’s expanded focus on healthcare career development, we are determined to help migrating nurses and other health professionals thrive at every stage of their careers. In the U.S., this means having the opportunity to take their understanding of the language from proficiency to mastery,” said Dr. Peter Preziosi, President and CEO of TruMerit.

    “We are delighted to be able to work with EnGen to address this challenge by making career-aligned English instruction available through the personalized, mobile-first learning experiences the company offers,” he said.

    “By equipping foreign-educated healthcare workers with job-specific English skills, we’re empowering them to communicate confidently with patients, deliver high-quality care, and succeed in high-stakes environments-while also thriving off the clock in their communities,” said Dr. Katie Brown, EnGen’s Founder and Chief Education Officer. “EnGen’s approach drives real-world results: 94% of our learners feel more confident using English at work, 93% save time on the job, and 92% have improved their job skills. Another 80% said they can navigate life better. We’re proud to partner with TruMerit to help build a stronger, future-ready healthcare workforce.”

    In addition to the healthcare-focused English instruction, EnGen also offers content aimed at helping learners navigate their new life in an English-speaking country, covering topics like social integration, legal, financial, and digital literacy, as well as U.S. citizenship test preparation.

    Additionally, to help accompanying spouses and other family members adjust, the offers available through TruMerit include special pricing on a family option, under which courses offered by EnGen can be accessed by family members aged 14 and above.

    About TruMerit
    TruMerit is a worldwide leader in healthcare workforce development. Formerly known as CGFNS International, the organization has a nearly 50-year history supporting the career mobility of nurses and other healthcare workers-and those who license and hire them-by validating their education, skills, and experience as they seek authorization to practice in the United States and other countries. As TruMerit, this mission has been expanded to building workforce capacity that meets the needs of people in a rapidly evolving global health landscape. Through its Global Health Workforce Development Institute, the organization is advancing evidence-based research, thought leadership, and advocacy in support of healthcare workforce development solutions, including globally recognized practice standards and certifications that will enhance career pathways for healthcare workers.

    About EnGen
    EnGen offers an at-scale, AI-powered approach to English instruction, designed to solve a systemic access issue: Adult English learners now represent 1 in 10 working-age adults in the U.S., yet the workforce system serves the needs of just 2% of these workers. A Certified B Corporation, EnGen is filling the gap by partnering with employers, adult educators, workforce development organizations, and state governments to connect job seekers and incumbent workers with English skills, career pathways, and employment in high-demand industries. EnGen’s workforce-aligned approach addresses employers’ recruitment and retention challenges and advances learners’ economic mobility. Learn more at getengen.com.

    Contact Information

    David St. John
    dstjohn@trumerit.org

    SOURCE: TruMerit

    View the original press release on ACCESS Newswire